Quick answers
- What is Valbenazine used for?
- The FDA-approved label (Ingrezza, Neurocrine Biosciences, Inc., April 17, 2026) says: “INGREZZA and INGREZZA SPRINKLE are indicated for the treatment of adults with: - tardive dyskinesia […]. - chorea associated with Huntington’s disease […]. INGREZZA and INGREZZA SPRINKLE are vesicular monoamine transporter 2 (VMAT2) inhibitors indicated for the treatment of adults with: - tardive dyskinesia. - chorea associated with Huntington’s disease.” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Valbenazine have a boxed warning?
- Yes. The FDA label for Ingrezza has a boxed warning, the FDA’s strongest warning. Read it on the full label and ask your pharmacist.
- Is there a shortage of Valbenazine?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Valbenazine been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Valbenazine?
- 1 company lists prescription products of Valbenazine in the FDA NDC Directory, including Neurocrine Biosciences, Inc..
What Valbenazine is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
INGREZZA and INGREZZA SPRINKLE are indicated for the treatment of adults with: - tardive dyskinesia […]. - chorea associated with Huntington’s disease […]. INGREZZA and INGREZZA SPRINKLE are vesicular monoamine transporter 2 (VMAT2) inhibitors indicated for the treatment of adults with: - tardive dyskinesia. - chorea associated with Huntington’s disease.
— FDA label: Ingrezza, Neurocrine Biosciences, Inc., effective April 17, 2026. Read the full label on DailyMed →
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
This label has a boxed warning. Read it on the full label →
Forms and how it is given
| Dosage forms | Capsule |
|---|---|
| Route | Oral |
| Prescription products | 6 in the FDA NDC Directory |
| Brand names | Ingrezza, Ingrezza Sprinkle |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| valbenazine tosylate 40 mg capsule | Brand: Ingrezza | $270.59 per capsule |
| valbenazine tosylate 60 mg capsule | Brand: Ingrezza | $291.82 per capsule |
| valbenazine tosylate 80 mg capsule | Brand: Ingrezza | $291.82 per capsule |
NADAC list of November 4, 2026; these prices took effect on October 16, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Neurocrine Biosciences, Inc.6 products
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Ingrezza, Neurocrine Biosciences, Inc., effective April 17, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →